Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo

Journal of Dermatology

Volumn 38, Issue 6, 2011, Pages 536-540

  Udompataikul, Montree ^a   Boonsupthip, Pairutch ^a   Siriwattanagate, Rungthiwa ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

adult; children; topical tacrolimus; vitiligo

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; ERYTHEMA; FEMALE; GROUPS BY AGE; HUMAN; MALE; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADULT; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TACROLIMUS; TREATMENT OUTCOME; VITILIGO;

EID: 79957909125     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01067.x     Document Type: Article

References (25)

1. Halder RM, Taliaferro SJ,. Vitiligo. In:, Wolff K, Goldsmith L, eds. Fitzpatrick's Dermatology in General Medicine, 7th edn. New York: McGrow-Hill Companies, Inc, 2008; 617-618.
2. Grimes PE,. XV Disorders of pigmentation. In:, Dale DC, Federman DD, eds. Dermatology, WebMD Scientific American Medicine. New York: WebMD Inc, 2003; 526-534.
3. Njoo MD, Westerhof W,. Vitiligo: pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-181. (Pubitemid 32488765)
4. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochem Biophys Acta 1994; 1226: 181-192. (Pubitemid 24182463)
5. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994; 74: 120-123. (Pubitemid 24102472)
6. Gould IM, Gray RS, Urbaniak SJ, et al. Vitiligo in diabetes mellitus. Br J Dermatol 1985; 113: 153-155. (Pubitemid 15018545)
7. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100. (Pubitemid 36596954)
8. Caixia T, Hongwen F, Xiran L,. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999; 21: 59-62. (Pubitemid 29347112)
9. Honda Y, Okubo Y, Koga M,. Relationship between levels of soluble interleukin-2 receptor and the types and activity of vitiligo. J Dermatol 1997; 24: 561-563. (Pubitemid 27454511)
10. Yeo UC, Yang YS, Park KB, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999; 19: 182-188. (Pubitemid 29172290)
11. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92. (Pubitemid 34536320)
12. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998; 134: 1532-1540. (Pubitemid 29009253)
13. Marsland AM, Griffiths CE,. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12: 618-622.
14. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic response and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51 (1 Pt 1): 52-61. (Pubitemid 38887475)
15. Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice daily topical tacrolimus: a controlled prospective, randomized observer-blinded trial. J Eur Acad Dermatol Venereal 2009; 23: 951-953.
16. Xu AE, Zhang DM, Wei XD, Huang B, Lu L,. Efficacy and safety of tacrolimus cream 0.1% in treatment of vitiligo. Int J Dermatol 2009; 48: 86-89.
17. Grimes PE, Soriano T, Dytoc MT,. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-791. (Pubitemid 35239348)
18. Tanghetti EA,. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-162. (Pubitemid 38010838)
19. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 760-766. (Pubitemid 39516891)
20. Kostovic K, Pasic A,. New treatment modalities for vitiligo. Drugs 2005; 66: 447-459.
21. Arrunategui A, Arroyo C, Garcia L, Covelli C, Carrascal E, Falabella R,. Melanocyte reservoir in vitiligo. Inst J Dermatol 1994; 33: 484-487. (Pubitemid 24227509)
22. 14C(U)-I-tyrosine incorperation into melanin. J Invest Dermatol 1982; 78: 243-252. (Pubitemid 12171889)
23. Ortonne JP, Schmitt D, Thivolet J,. PUVA-induced repigmentation of vitiligo scanning electron microscopy of hair follicles. J Invest Dermatol 1980; 74: 40-42. (Pubitemid 10134598)
24. Cui L, Shen LY, Wang GC,. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97: 410-416.
25. Parsad D, Pandhi R, Dogra S, Kumar B,. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiligonous patches. J Am Acad Dermatol 2004; 50: 63-67. (Pubitemid 38095653)